Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | CALML3 | P27482 | 7/20 | 0.39 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SDHA | P31040 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24296584 | 0.88 | CALML3 (0.51) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL21690967 | 0.86 | MAOA (0.46) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL21690952 | 0.86 | MAOA (0.46) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL20333356 | 0.84 | MAOA (0.44) | MAOACALML3MAOB | |
| SCHEMBL18770292 | 0.84 | MAOA (0.69) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL18410619 | 0.84 | MAOA (0.69) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL23847768 | 0.84 | MAOA (0.43) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL13939816 | 0.83 | MAOA (0.43) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL13515445 | 0.83 | MAOA (0.73) | MAOAF10CALML3MAOBLMNA | |
| SCHEMBL23833817 | 0.82 | MAOA (0.51) | MAOAF10CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | H1-0, NGLY1, H1-5 | MAOA 1576/4885F10 1215/4885CALML3 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.